Mohr, P.; Scherrer, E.; Assaf, C.; Bender, M.; Berking, C.; Chandwani, S.; Eigentler, T.; Grimmelmann, I.; Gutzmer, R.; Haferkamp, S.;
et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers 2022, 14, 1804.
https://doi.org/10.3390/cancers14071804
AMA Style
Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, Grimmelmann I, Gutzmer R, Haferkamp S,
et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers. 2022; 14(7):1804.
https://doi.org/10.3390/cancers14071804
Chicago/Turabian Style
Mohr, Peter, Emilie Scherrer, Chalid Assaf, Marc Bender, Carola Berking, Sheenu Chandwani, Thomas Eigentler, Imke Grimmelmann, Ralf Gutzmer, Sebastian Haferkamp,
and et al. 2022. "Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany" Cancers 14, no. 7: 1804.
https://doi.org/10.3390/cancers14071804
APA Style
Mohr, P., Scherrer, E., Assaf, C., Bender, M., Berking, C., Chandwani, S., Eigentler, T., Grimmelmann, I., Gutzmer, R., Haferkamp, S., Hassel, J. C., Hauschild, A., Herbst, R., Jiang, R., Kähler, K. C., Krepler, C., Kreuter, A., Leiter, U., Loquai, C.,
... Weichenthal, M.
(2022). Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers, 14(7), 1804.
https://doi.org/10.3390/cancers14071804
